<DOC>
	<DOCNO>NCT00979966</DOCNO>
	<brief_summary>This prospective , open-label , randomized multicenter phase-II study evaluate progression free survival ( PFS ) patient locally advanced metastatic non-clear cell renal cell cancer ( ncc-RCC ) receive Temsirolimus comparison Sunitinib . In clinical trial renal cell carcinoma ( RCC ) , clear cell RCC include exclusively . There limited data efficacy Temsirolimus Sunitinib ncc-RCC show interesting response rate agent . However , randomize clinical trial specific patient population yet perform . In proposed study comparison Temsirolimus Sunitinib schedule first line therapy ncc-RCC .</brief_summary>
	<brief_title>Study Non-Clear Cell Renal Carcinoma ( Ncc-RCC ) Temsirolimus Versus Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Adult male female : ≥18 year age . 2 . Locally advanced metastatic , histological confirm , nonclear cell RCC subtypes . Patients must advance nonclear cell one follow subtypes : papillary , chromophobe , collect duct carcinoma ( CDC ) , renal medullary carcinoma ( RMC ) , unclassified . 3 . Patients measurable disease ( least one unidimensionally measurable target lesion CTscan MRI ) accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) If prior palliative radiotherapy metastatic lesion : ≥ 1 measurable lesion irradiate . 4 . PS 02 ECOG 5 . Signed write informed consent . 6 . White blood cell count ( WBC ) ≥4x10*9/L neutrophils ≥1.5 x 10*9/L , platelet count ≥100x10*9/L , hemoglobin ≥9 g/dL . ] 7 . Total bilirubin &lt; 2 x upper limit normal . 8 . AST ALT &lt; 2.5 x upper limit normal , &lt; 5 x upper limit normal case liver metastasis . 9 . Serum creatinine &lt; 2.0 x upper limit normal . 10 . Normal ECG without QT prolongation ( QTc &lt; 450msec ) . 11 . Adequate cardiac function ( left ventricular ejection fraction &gt; 40 % assessed ECHO . 1 . Predominant clearcell RCC 2 . Resectability curative option 3 . Any investigational drug within 30 day inclusion . 4 . Prior systemic treatment RCC . 5 . Known suspected allergy hypersensitivity reaction component study treatment . 6 . Radiotherapy within last 4 week . 7 . Pregnancy ( absence confirm betahCG test ) lactation period . 8 . Men woman childbearing potential sexually active unwilling use medically acceptable method contraception trial . 9 . Clinically symptomatic brain meningeal metastasis . ( know suspect ) 10 . Cardiac arrhythmia require antiarrhythmic ( exclude beta blocker digoxin ) . 11 . History follow cardiac event within past 6 month : myocardial infarction ( include severe/unstable angina ) , coronary/peripheral artery bypass graft , congestive heart failure ( CHF ) , cerebrovascular accident , transient ischemic attack , pulmonary embolism . 12 . No hemorrhage ≥ grade 3 within past 4 week 13 . Uncontrolled severe hypertension ( failure diastolic blood pressure fall 90 mm Hg despite use ≥3 antihypertensive drug 14 . History relevant pulmonary hypertension interstitial lung disease . 15 . Acute subacute intestinal occlusion history inflammatory bowel disease chronic diarrhea 16 . Previous malignancy ( renal cancer cancer ) last 5 year except basal cell cancer skin , preinvasive cancer cervix superficial bladder tumor [ Ta , Tis T1 ] . 17 . History organ allograft 18 . Significant disease , investigator ` opinion would exclude patient study 19 . Patients seizure epileptic disorder condition require medication ( phenytoin , carbamazepin , phenobarbital ) 20 . Patients strong inducer inhibitor CYP Isoenzymes 21 . Patients hypersensitivity antihistamine patient receive antihistamine medical reason 22 . Patients require longterm cortisone therapy 23 . Patients require oral anticoagulation treatment , marcoumar . ( Anticoagulation treatment heparin low molecular weight heparin [ LMWH ] allow provide close monitoring perform ) . 24 . Surgery within least 2 week prior randomization 25 . HIV seropositivity . 26 . Abnormal pulmonary function ( DLCO &lt; 50 % ) . [ Pulmonary function test need perform abnormal pulmonary function present medical history ] . 27 . Poorly control diabetes mellitus . 28 . Liver cirrhosis , chronic hepatitis 29 . Legal incapacity limit legal capacity 30 . Known alcohol drug abuse . 31 . Medical psychological condition would permit patient complete study sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Locally advanced metastatic non-clear cell renal cell cancer ( ncc-RCC )</keyword>
</DOC>